Predictive classifier for intensive treatment of head and neck cancer.
altered fractionation
chemotherapy
competing risks
head and neck cancer
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
31
03
2020
revised:
24
05
2020
accepted:
10
06
2020
pubmed:
6
10
2020
medline:
21
5
2021
entrez:
5
10
2020
Statut:
ppublish
Résumé
This study was designed to test the hypothesis that the effectiveness of intensive treatment for locoregionally advanced head and neck cancer (LAHNC) depends on the proportion of patients' overall event risk attributable to cancer. This study analyzed 22,339 patients with LAHNC treated in 81 randomized trials testing altered fractionation (AFX; Meta-Analysis of Radiotherapy in Squamous Cell Carcinomas of Head and Neck [MARCH] data set) or chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC] data set). Generalized competing event regression was applied to the control arms in MARCH, and patients were stratified by tertile according to the ω score, which quantified the relative hazard for cancer versus competing events. The classifier was externally validated on the MACH-NC data set. The study tested for interactions between the ω score and treatment effects on overall survival (OS). Factors associated with a higher ω score were a younger age, a better performance status, an oral cavity site, higher T and N categories, and a p16-negative/unknown status. The effect of AFX on OS was greater in patients with high ω scores (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.85-0.99) and medium ω scores (HR, 0.91; 95% CI, 0.84-0.98) versus low ω scores (HR, 0.97; 95% CI, 0.90-1.05; P for interaction = .086). The effect of chemotherapy on OS was significantly greater in patients with high ω scores (HR, 0.81; 95% CI, 0.75-0.88) and medium ω scores (HR, 0.86; 95% CI, 0.78-0.93) versus low ω scores (HR, 0.96; 95% CI, 0.86-1.08; P for interaction = .011). LAHNC patients with a higher risk of cancer progression relative to competing mortality, as reflected by a higher ω score, selectively benefit from more intensive treatment.
Sections du résumé
BACKGROUND
This study was designed to test the hypothesis that the effectiveness of intensive treatment for locoregionally advanced head and neck cancer (LAHNC) depends on the proportion of patients' overall event risk attributable to cancer.
METHODS
This study analyzed 22,339 patients with LAHNC treated in 81 randomized trials testing altered fractionation (AFX; Meta-Analysis of Radiotherapy in Squamous Cell Carcinomas of Head and Neck [MARCH] data set) or chemotherapy (Meta-Analysis of Chemotherapy in Head and Neck Cancer [MACH-NC] data set). Generalized competing event regression was applied to the control arms in MARCH, and patients were stratified by tertile according to the ω score, which quantified the relative hazard for cancer versus competing events. The classifier was externally validated on the MACH-NC data set. The study tested for interactions between the ω score and treatment effects on overall survival (OS).
RESULTS
Factors associated with a higher ω score were a younger age, a better performance status, an oral cavity site, higher T and N categories, and a p16-negative/unknown status. The effect of AFX on OS was greater in patients with high ω scores (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.85-0.99) and medium ω scores (HR, 0.91; 95% CI, 0.84-0.98) versus low ω scores (HR, 0.97; 95% CI, 0.90-1.05; P for interaction = .086). The effect of chemotherapy on OS was significantly greater in patients with high ω scores (HR, 0.81; 95% CI, 0.75-0.88) and medium ω scores (HR, 0.86; 95% CI, 0.78-0.93) versus low ω scores (HR, 0.96; 95% CI, 0.86-1.08; P for interaction = .011).
CONCLUSIONS
LAHNC patients with a higher risk of cancer progression relative to competing mortality, as reflected by a higher ω score, selectively benefit from more intensive treatment.
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5263-5273Subventions
Organisme : UC San Diego Head and Neck Cancer Center
Organisme : Programme d'Actions Intégrées de Recherche
ID : 2011-1-VADS-04
Organisme : Ligue National Contre le Cancer, Institut National du Cancer
ID : PHRC-K 10-02-58
Organisme : Ligue National Contre le Cancer, Institut National du Cancer
ID : PHRC-K-15-189
Informations de copyright
© 2020 American Cancer Society.
Références
Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): an update on 93 randomised trials and 17 346 patients. Radiother Oncol. 2009;92:4-14.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-28.
Porceddu SV, Haddad RI. Management of elderly patients with locoregionally confined head and neck cancer. Lancet Oncol. 2017;18:e274-e283.
Amini A, Jones BL, McDermott JD, et al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016;122:1533-1543.
Juarez JE, Choi J, St John M, Abemayor E, TenNapel M, Chen AM. Patterns of care for elderly patients with locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2017;98:767-774.
VanderWalde NA, Meyer AM, Liu H, et al. Patterns of care in older patients with squamous cell carcinoma of the head and neck: a Surveillance, Epidemiology, and End Results-Medicare analysis. J Geriatr Oncol. 2013;4:262-270.
VanderWalde NA, Meyer AM, Deal AM, et al. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014;89:30-37.
Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26:3582-3589.
Carmona R, Zakeri K, Green G, et al. Improved method to stratify elderly patients with cancer at risk for competing events. J Clin Oncol. 2016;34:1270-1277.
Carmona R, Gulaya S, Murphy JD, et al. Validated competing event model for the stage I-II endometrial cancer population. Int J Radiat Oncol Biol Phys. 2014;89:888-898.
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Br J Cancer. 2015;112:251-259.
Bourhis J, Overgaard J, Audry H, et al; Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843-854.
Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221-1237.
Michiels S, Le Maitre A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol. 2009;10:341-350.
Comprehensive R Archive Network. Package ‘gcerisk.’ Accessed March 5, 2019. https://cran.r-project.org/web/packages/gcerisk/gcerisk.pdf
Lueza B, Rotolo F, Bonastre J, Pignon JP, Michiels S. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Med Res Methodol. 2016;16:37.
Lassen P, Lacas B, Pignon JP, et al; MARCH Collaborative Group. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 2018;126:107-115.
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
Fakhry C, Zhang Q, Nguyen-Tan PF, et al. Development and validation of nomograms predictive of overall survival and progression-free survival in patients with oropharyngeal cancer. J Clin Oncol. 2017;35:4057-4065.
Zakeri K, Rose BS, Gulaya S, D’Amico AV, Mell LK. Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794. Contemp Clin Trials. 2013;34:74-79.
Zakeri K, Rose BS, D’Amico AV, Jeong JH, Mell LK. Competing events and costs of clinical trials: analysis of a randomized trial in prostate cancer. Radiother Oncol. 2015;115:114-119.
Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13:e437-e444.
Puts MT, Hardt J, Monette J, Girre V, Springall E, Alibhai SM. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst. 2012;104:1133-1163.
VanderWalde NA, Deal AM, Comitz E, et al. Geriatric assessment as a predictor of tolerance, quality of life, and outcomes in older patients with head and neck cancers and lung cancers receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98:850-857.
Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck carcinoma patients. Cancer. 2001;92:2109-2116.
Mell LK, Shen H, Nguyen-Tan PF, et al. Nomogram to predict the benefit of intensive treatment for locoregionally advanced head and neck cancer. Clin Cancer Res. 2019;25:7078-7088.
Park A, Alabaster A, Shen H, Mell LK, Katzel JA. Undertreatment of women with locoregionally advanced head and neck cancer. Cancer. 2019;125:3033-3039.
Vitzthum LK, Park H, Zakeri K, et al. Selection of head and neck cancer patients for intensive therapy. Int J Radiat Oncol Biol Phys. 2020;106:157-166.